BioCentury
ARTICLE | Financial News

Versant leads Tarveda’s $30M D round

February 2, 2017 9:18 PM UTC

Tarveda Therapeutics Inc. (Watertown, Mass.) said it raised $30 million in a series D round led by new investor Versant Ventures. Existing investors New Enterprise Associates, Novo A/S, NanoDimension and Flagship Pioneering also participated.

Tarveda uses its Pentarin platform to develop miniaturized antibody-drug conjugates (ADCs), which it says offer greater tumor penetration than traditional ADCs, with sustained payload release. The company's lead candidate, PEN-221, targets somatostatin receptor 2 (SSTR2) and uses a DM1 cytotoxic agent. ...